Effects of exercise on the markers of iron status in serum of cross-country skiers

The study aim was to assess the within-subject, day-to-day variability for ferritin and soluble transferrin receptor (sTfR) concentrations in serum of 6 female and 8 male cross-country skiers aged 16-18 years under a regular training regimen throughout 8 consecutive days. The concentrations of iron status variables and creatine kinase (CK) activities were adjusted to plasma volume changes. Mean ferritin concentrations were 30.6 • 1.142[sup]±1[/sup] and 22.6 • 1.167[sup]±1[/sup] μg/l for men and women, respectively, the average within-subject, mean day-to-day variability coefficients (CV) being 13.4% in men and 15.2% in women. Mean sTfR was 2.14 • 1.050[sup]±1[/sup] and 2.62 • 1.047[sup]±1[/sup] mg/l, respectively, and mean day-to-day CV 6.5% and 4.6%. Mean CV for sTfR/logFerr were 6.0% and 7.4%, respectively. Neither index correlated with training loads or CK activities. Thus, the training performed once daily had no significant effect on ferritin concentrations on the following morning, so ferritin alone may prove insufficient in detecting iron deficiency in endurance athletes. The low variability of sTfR under endurance loads made it useful in detecting iron deficiency together with ferritin and the sTfR/logFerr index. Adjusting the concentrations of ferritin and sTfR by changes in plasma volume might be recommendable for endurance athletes

Improvement of non-steroidal anti-inflammatory drug-induced gastrointestinal symptoms during proton pump inhibitor treatment: are G-protein beta3 subunit genotype, helicobacter pylori status, and environmental factors response modifiers?

BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with significant upper and lower gastrointestinal (GI) morbidity. AIM: To determine the efficacy and safety of pantoprazole versus placebo in controlling GI symptoms during treatment with NSAIDs and to evaluate the influence of potential response modifiers. METHODS: 800 patients with GI complaints during NSAID treatment were randomized to pantoprazole 20 mg once daily or placebo for 4 weeks in this double-blind, multicenter trial. Assessments included the difference in cumulated overall symptom load of any GI complaint during treatment (primary endpoint), proportion of days without GI symptoms, and influence of risk factors such as gender, age, alcohol consumption, smoking, Helicobacter pylori status, and GNB3 genotype SNP rs5443 (825C>T) on symptom load. RESULTS: At 4 weeks, cumulated overall symptom load was significantly lower in pantoprazole than placebo recipients [p < 0.0001; intent-to-treat (ITT)]; the effect was statistically significant after 7 days’ treatment. Pantoprazole versus placebo recipients had 54 versus 29% of days without GI symptoms (p < 0.0001; ITT). Neither common risk factors nor GNB3 genotype were significantly associated with therapeutic response, while GNB3 825TT versus CT was associated with a significantly higher baseline symptom load (p < 0.05). Conclusion: In the population studied, treatment with the proton pump inhibitor pantoprazole significantly improves GI symptoms during NSAID therapy, irrespective of the risk factors investigated or GNB3 genotype